Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Payables (2020 - 2025)

Historic Payables for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $1.3 million.

  • Maxcyte's Payables fell 3104.56% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 3104.56%. This contributed to the annual value of $1.4 million for FY2024, which is 8277.25% up from last year.
  • According to the latest figures from Q3 2025, Maxcyte's Payables is $1.3 million, which was down 3104.56% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Maxcyte's Payables registered a high of $4.4 million during Q1 2022, and its lowest value of $292000.0 during Q4 2022.
  • For the 5-year period, Maxcyte's Payables averaged around $1.6 million, with its median value being $1.5 million (2023).
  • Per our database at Business Quant, Maxcyte's Payables tumbled by 8395.87% in 2022 and then soared by 31759.96% in 2024.
  • Over the past 5 years, Maxcyte's Payables (Quarter) stood at $1.8 million in 2021, then tumbled by 83.96% to $292000.0 in 2022, then skyrocketed by 154.45% to $743000.0 in 2023, then skyrocketed by 82.77% to $1.4 million in 2024, then fell by 5.3% to $1.3 million in 2025.
  • Its Payables was $1.3 million in Q3 2025, compared to $1.2 million in Q2 2025 and $2.3 million in Q1 2025.